Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy : Initial and follow-up results in the first 27 patients

Circulation Journal

Volumn 67, Issue 9, 2003, Pages 763-767

  Tsuchikane, Etsuo ^a   Takeda, Yoshihiro ^a   Kobayashi, Tohru ^a   Yachiku, Kenji ^a   Nasu, Kenya ^a   Kobayashi, Yoshiki ^a   Matsumoto, Hiroaki ^a   Awata, Nobuhisa ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Hypertrophic obstructive cardiomyopathy; Percutaneous myocardial ablation; Septal infarction

Indexed keywords

CREATINE KINASE;

ADULT; AGED; ARTICLE; CATHETER ABLATION; CLINICAL ARTICLE; CONTRAST ECHOCARDIOGRAPHY; CREATINE KINASE BLOOD LEVEL; FEMALE; FOLLOW UP; HEART BLOCK; HEART CATHETERIZATION; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE WALL; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; MITRAL VALVE REGURGITATION; PERCUTANEOUS TRANSLUMINAL SEPTAL MYOCARDIAL ABLATION; PRESSURE GRADIENT; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0042821502     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.67.763     Document Type: Article

References (25)

1. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214.
2. Tsuchikane E, Nakamura T, Yamazaki K, Kitano K, Izumi M, Otsuji S, et al. Transluminal percutaneous septal myocardial ablation in a patient with hypertrophic obstructive cardiomyopathy. Jpn Circ J 1998; 62: 537-540.
3. Ciro E, Nichols PF III, Maron BJ. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy: Two-dimensional echocardiographic analysis. Circulation 1983; 67: 1227-1233.
4. Hamada M, Shigematsu Y, Hara Y, Suzuki M, Hiasa G, Ogimoto A, et al. Antiarrhythmic drug, cibenzolie, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Circ J 2001; 65: 531-538.
5. McIntosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation 1988; 78: 487-495.
6. Mohr R, Schaff HV, Danielson GK, Puga FJ, Pluth JR, Tajik AJ. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy: Experience over 15 years. J Thorac Cardiovasc Surg 1989; 97: 666-674.
7. McDonald K, McWilliams E, O'Keeffe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment of hypertrophic cardiomyopathy. Eur Heart J 1988; 9: 893-899.
8. Jeanrenaud X, Goy J-J, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992; 339: 1318-1323.
9. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment of drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: A randomized, double-blind, cross-over study (M-PATHY). Circulation 1999; 99: 2927-2933.
10. Meisel E, Rauwolf T, Burghardt M, Kappenberger L. Pacemaker therapy of hypertrophic obstructive cardiomyopathy. PIC (pacing in cardiomyopthy) study group. Herz 2000; 25: 461-466.
11. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 1997; 95: 2075-2081.
12. Seggewiss H, Faber L, Gleichman U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999; 47: 94-100.
13. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998; 98: 1750-1755.
14. Ruzyllo W, Chojnowaka L, Demkow M, Witkowski A, Kusmierczyk-Droszcz B, Piotrowski W, et al. Left ventricular outflow gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J 2000; 21: 770-777.
15. Faber L, Seggewiss H, Gleichman U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intracoronary myocardial contrast echocardiography. Circulation 1998; 98: 2415-2421.
16. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 1701-1706.
17. Okayama H, Sumimoto T, Morioka N, Yamamoto K, Kawada H. Usefulness of selective myocardial contrast echocardiography in percutaneous transluminal septal myocardial ablation: A case report. Circ J 2001; 65: 842-844.
18. Nagueh SF, Lakkis NM, Middeton KJ, Killip D, Zoghbi WA, Quinones MA, et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1999; 34: 1123-1128.
19. Nagueh SF, Lakkis NM, Middeton KJ, Killip D, Zoghbi WA, Quinones MA, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999; 99: 344-347.
20. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Long term follow up of the first series of 25 patients. Heart 2000; 83: 326-331.
21. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000; 36: 852-855.
22. Mazur W, Nagueh SF, Lakkis NM, Middeton KJ, Killip D, Roberts R, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 103: 1492-1496.
23. Welge D, Faber L, Seggewiss H, Fassbender D, Gleichmann U, Horstkotte D. Long-term outcome after percutaneous septal ablation for hypertrophic obstructive cardiomyopathy (abstract). Circulation 2002; 106(Suppl): 11-710.
24. Hirata K, Wake M, Asato H, Kyushima M, Serizawa Y. Sudden death of a case of hypertrophic obstructive cardiomyopathy 19 months after successful percutaneous transluminal septal myocardial ablation. Circ J 2003; 67: 559-561.
25. Qin JX L, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001; 38: 1994-2000.